Fibrinogen is a crucial haemostatic factor in sustaining platelet aggregation via glycoprotein (GP) IIb/IIIa receptors during primary haemostasis. Platelet-bound fibrinogen is subsequently cleaved to fibrin monomers by thrombin, and fibrin monomers are polymerized by thrombin-activated factor XIII, resulting in secondary haemostasis. Very low fibrinogen concentrations with normal platelet count have been linked to an unstable clot formation. 1 2 Conversely, high fibrinogen concentrations are speculated to compensate for thrombocytopenia, as suggested in experimental and animal studies. [3] [4] [5] [6] Platelet concentrates are often expensive, and perioperative transfusion of allogeneic platelets has been associated with an increased risk of stroke, 7 allergic reaction, pathogen transmission and immunodulation. 8 There has been increasing interest in platelet alternatives in perioperative haemostasis, amongst them is the infusion of fibrinogen concentrate (FC). 3 4 6 9-11 The latter has been claimed by some authors as a "universal haemostatic agent". 12 13 In a recent issue of the British Journal of Anaesthesia, Schenk and colleagues 14 compared the effects of ex vivo spiking with FC, and in vivo platelet transfusion on viscoelastic clot strength, using rotational thromboelastometry (ROTEM V R ; TEM International, Munich, Germany). Their hypothesis and aims are based on the assumption that enhanced fibrin polymerization proportionally increases clot strength, even in the presence of thrombocytopenia and/or platelet dysfunction. 3-6 15 The platelet transfusion was deemed necessary by the physician in charge as I. Indication of platelet transfusion was clinically determined as a treatment for microvascular bleeding, and the mean platelet count was 88 x 10 9 l À 1 before transfusion. Thirty percent of their patients had been treated with one of P2Y 12 inhibitors before surgery. Despite there is a wide variability in the practice of platelet transfusion, [16] [17] [18] these data would rather support the use of platelet concentrate. The efficacy of platelet transfusion has been questioned, 16 17 19 and is mostly guessed from an increase in platelet count or by reduced bleeding tendency. 20 Schenk and colleagues 14 documented a dose-dependent increase in platelet count after platelet transfusion. More GPIIb/IIIa receptors become available with a higher platelet count, which increases fibrin interactions, and viscoelastic clot strength. The effects of P2Y 12 inhibitors are not reflected on thromboelastometry, because thrombin-induced platelet activation sustains the active state of GPIIb/IIIa receptors. 21 A previously published comparative study of ex vivo FC supplementation (100-400 mg kg
, and in vivo platelet transfusion in thrombocytopenia as a result of bone marrow failure, also demonstrated the similar viscoelastic effects on thromboelastometry (ROTEM V R ; TEM International, Munich, Germany). 5 However, clinical implication of FC in that study was highly questionable because the fibrinogen concentration was 4.5 g l À 1 , while platelet count was 17 x 10 9 l À 1 at baseline. Clinical platelet transfusion is obviously aimed to increase platelet accumulations at the site of vascular injury, but ROTEM V R is not designed to evaluate such effects. II. In vitro addition of fibrinogen to thrombocytopenic blood increases viscoelastic clot strength in a concentrationdependent manner on ROTEM V R . 4 ) vs homologous platelet transfusion. In clinical practice, the first-line use of FC as a haemostatic intervention remains controversial in the cardiac surgical setting. There have been three recent studies which tested the effect of FC, as a first-line therapy to reduce allogeneic blood usage including platelets. In a small prospective randomized study including 20 patients who underwent valvular heart surgery, the administration of 4 g of FC resulted in similar postoperative bleeding volumes, and erythrocyte transfusion compared with the transfusion of 1 unit of apharesis platelets. 23 Ranucci and colleagues 24 conducted a prospective randomized placebo-controlled study of FC, which showed that a high normal fibrinogen concentration maintained by FC supplementation (median, 4 g), was effective in reducing the transfusion of erythrocytes, plasma, and platelets in complex cardiac surgery. In contrast, Rahe-Meyer and colleagues 25 25 mm, which were below those achieved in the REPLACE study. It is thus difficult to simply link higher fibrinogen concentrations or viscoelastic clot strength to clinical efficacy of FC. It remains controversial to target very high fibrinogen concentrations using FIBTEM-MCF. Indeed, Ranucci and colleagues 24, 26 speculated that increasing FIBTEM-MCF above 14 mm, was not associated with further conservation of allogeneic blood products, based on the secondary analysis of their prospective FC intervention data. III. Viscoelastic clot strength was used as a surrogate of potential haemostatic efficacy, but caution should be exercised in the interpretation. The low-shear environment (0.1 s À 1 ) of thromboelastometry, preferentially shows fibrin polymerization over platelet activity under high-shear conditions. Anaemia appears to differently affect thromboelastometry and in vivo coagulation. Viscoelastic clot strength tends to increase in the presence of anaemia, 27 28 while anaemia seems to exacerbate microvascular bleeding via reduced platelet margination to vessel walls during blood flow. 29 The effect of fibrinogen on viscoelastic clot strength may be overestimated in vitro, especially under anaemic state, and can, therefore, not be directly compared with in vivo platelet activity. On viscoelastic coagulation assays, fibrin itself can generate viscoelasticity without platelets, 30 and thus increased clot strength does not guarantee improved interactions between aggregating platelets and fibrinogen. Further, ROTEM V R is rather insensitive to impaired platelet function as a result of intake of P2Y 12 receptor antagonists and shows usually normal findings in patients with dual platelet inhibitiors. 20 31 Indeed, ex vivo addition of FC (100 mg kg À 1 ) to the whole blood obtained from patients receiving P2Y 12 receptor antagonist therapy showed improved clot strength on thromboelastometry, but platelet aggregation induced by either adenosine 5'-disphosphate or thrombin receptor agonist peptide was not improved. 32 In summary, the work of Schenk and colleagues 14 suggests an interesting alternative to platelet transfusion. Further testing of prophylactic or therapeutic fibrinogen administration as a haemostatic therapy to reduce platelet transfusion in thrombocytopenic patients seems to worth the effort. However, haemostatic reactions in vivo are inherently complex, and therefore, only limited information can be obtained from a single coagulation test such as ROTEM V R . Further, primary fibrinogen replacement might not work well for severe dilutional coagulopathy, 33 or P2Y 12 receptor antagonist-induced thrombocytopathy. In the light of recently published studies, 24 25 34 aiming at extremely high concentrations of fibrinogen (>2.8 g L À 1 ) is questionable, 26 and its indication should be limited to bleeding patients with hypofibrinogenaemia until future evidence supports otherwise.
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